HOLDEN, Mass., Sept. 14 Today, Hygeia Therapeutics, Inc. ("Hygeia") announced the appointment of Elkan Gamzu, Ph.D. as Chairman to its Board of Directors. Dr. Gamzu has nearly 40 years of pharmaceutical and biotechnology experience and has held senior executive positions including CEO of Pharmos Corporation, Vice President of Project Management at Millenium Pharmaceuticals, CEO of Cambridge Neuroscience, Vice President of Drug Development at Warner-Lambert, senior research positions at Hoffmann-LaRoche, and most recently, CEO of EPIX Pharmaceuticals.
Advertisement
"Elkan brings a remarkable track record and a tremendous breadth of experience to our Board," said Yael Schwartz, Ph.D., CEO and President of Hygeia. "His expertise in drug development, clinical and regulatory affairs, combined with his exceptional knowledge of the industry will be an outstanding asset to Hygeia as we continue to build and advance our pipeline."
Advertisement
"I am honored to accept this position with Hygeia, especially given the tremendous potential of the pipeline to develop products that can greatly improve the quality of life of patients, while minimizing the risk," said Dr. Gamzu.
Dr. Gamzu has served on several boards of public companies: Cambridge NeuroScience, EPIX Pharmaceuticals and Pharmos, XTL. He has also served on several boards of private companies: AviTx, Hypnion, NeuroHealing, Neurotech, and the Board of Governors of the New York Academy of Sciences. Dr. Gamzu is a graduate of Hebrew University in Jerusalem and earned his Master's and Ph.D. degrees in experimental and physiological psychology from the University of Pennsylvania.
About Hygeia Therapeutics, Inc.
Hygeia acquires and develops biodegradable hormone-receptor modulators for topical indications. Hygeia products are all designed to be rapidly deactivated by enzymes at or near the site of application after the therapeutic effects are achieved. By avoiding the formation of active or toxic metabolites, Hygeia topical drugs are expected to have negligible systemic effects and have a better safety profile than other drugs in their therapeutic class. Hygeia assets were obtained by an exclusive license with Yale University.
SOURCE Hygeia Therapeutics, Inc.
